Sandbox:khurram: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 35: Line 35:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
!PTT
!aPTT
!Peripheral blood smear
!Peripheral blood smear
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding time
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding time
Line 50: Line 50:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
|<nowiki>-</nowiki>
|<nowiki>-</nowiki>
|<nowiki>-</nowiki>
|<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 153: Line 153:
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Decreased
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Increased
|
|Increased
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Increased
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 164: Line 164:
| style="background: #F5F5F5; padding: 5px;" |Ristocetin cofactor assay
| style="background: #F5F5F5; padding: 5px;" |Ristocetin cofactor assay
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Elevated fibrin degradation products
* Elevated D-dimer levels
|-
|-
|Antiphospholipid  antibody syndrome
|Antiphospholipid  antibody syndrome

Revision as of 18:47, 23 August 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]

On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Symptoms of DVT Symptoms of Pulmonary Embolism Symptoms of Myocardial Infarction Tenderness in extremities Edema in extremities Warmth in extremities Skin necrosis Platelet count PT aPTT Peripheral blood smear Bleeding time Doppler ultrasound Chest CT scan Head CT with contrast
Antithrombin deficiency - - - - -
  • Nephrotic syndrome
  • Decreased inhibition of factor II and Xa
  • Antithrombin is a natural anticoagulant that is lost in the urine
Factor V Leiden mutation
Protein C deficiency
Protein S deficiency
Prothrombin gene mutation
DIC Decreased Increased Increased Increased Ristocetin cofactor assay
  • Elevated fibrin degradation products
  • Elevated D-dimer levels
Antiphospholipid antibody syndrome
Heparin induced thrombocytopenia (HIT)

References

Template:WH Template:WS